Don't Cry Too Hard for Avandia
This article was originally published in RPM Report
Executive Summary
GSK suffered a major commercial loss after news of Avandia's cardiovascular safety exploded onto the market in 2007. But there is a sliver of a silver lining for GSK: FDA's post-Avandia safety rules may make it tougher for new competing products to reach the market.
You may also be interested in...
FDA’s First “Program” Reviews: Fast Approvals, But Still Some Surprises
The Food & Drug Administration is approving the first products under the new PDUVA V review process. The Program, as it is known, gives FDA an extra two months with an application in exchange for additional meetings for sponsors. It’s designed to help reduce the number of late-cycle “surprises.” There have been a few hiccups, but so far, it appears to be doing just that.
Regulatory Risk and Business Development: Type 2 Diabetes Falls Out of Favor
It's a buyer's market for type 2 diabetes drugs, and you can thank FDA for that. At least, that is the sentiment of business development executives from Big Pharma. Transaction data in 2008 back up that view.
Avandia's Black Box: FDA's Office of New Drugs Wins
The decision by FDA to add another "black box" warning to GalxoSmithKline's diabetes drug shows where the drug safety group stands on the agency's totem pole.